Apogee Therapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

992.07 k

Shareholding (Mar 2025)

FII

13.34%

Held by 92 FIIs

DII

38.33%

Held by 50 DIIs

Promoter

4.90%

How big is Apogee Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Apogee Therapeutics, Inc. has a market capitalization of $2.48 billion, with net sales of $0.00 million and a net profit of -$205.40 million over the last four quarters. The company reported shareholder's funds of $716.79 million and total assets of $753.95 million as of Dec 24.

What does Apogee Therapeutics, Inc. do?

22-Jun-2025

Apogee Therapeutics, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $55 million and a market cap of $2.48 billion. The company has no dividend yield and negative return on equity.

Is Apogee Therapeutics, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Apogee Therapeutics, Inc. shows a neutral technical trend with mixed signals, being mildly bullish on weekly indicators but bearish on daily ones, while outperforming the S&P 500 in the short term but underperforming over the past year.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,290 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.81

Return on Equity

-38.37%

Price to Book

3.70

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-66 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

97.85%

6 Months

103.61%

1 Year

63.21%

2 Years

279.97%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Apogee Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Apogee Therapeutics, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Apogee Therapeutics, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across different indicators. The weekly MACD is bullish, while the monthly MACD shows no signal. Bollinger Bands are bullish on both weekly and monthly time frames. However, the daily moving averages indicate a mildly bearish trend, and the KST is bearish on a weekly basis. Dow Theory suggests a mildly bullish outlook on both weekly and monthly time frames, while OBV shows a mildly bullish weekly stance but is mildly bearish monthly. In terms of performance, Apogee has outperformed the S&P 500 over the past week and month, with returns of 35.53% and 46.34% respectively, compared to the S&P 500's -2.43% and 0.31%. However, over the past year, Apogee has underperformed, with a return of -5.22% against the S&P 500's 13.36%....

Is Apogee Therapeutics, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Apogee Therapeutics, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed signals across various indicators. The MACD is bullish on the weekly timeframe but shows no signal on the monthly. The Bollinger Bands are bullish on both weekly and monthly timeframes, while the moving averages indicate a mildly bearish trend on the daily. The KST is bearish weekly, and the OBV shows a mildly bullish trend weekly but mildly bearish monthly. Dow Theory reflects a mildly bullish stance on both weekly and monthly timeframes. In terms of performance, Apogee has outperformed the S&P 500 over the past week and month, with returns of 31.57% and 39.96% respectively, compared to the S&P 500's -2.43% and 0.31%. However, the one-year return is negative at -2.67%, while the S&P 500 has gained 13.36%....

Is Apogee Therapeutics, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Apogee Therapeutics, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is bullish, while the monthly MACD shows no signal. Bollinger Bands are bullish on both weekly and monthly time frames. However, the daily moving averages are mildly bearish, and the KST is bearish on a weekly basis. Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames, while the OBV shows a mildly bullish weekly trend but is mildly bearish monthly. In terms of performance, Apogee has outperformed the S&P 500 over the past week and month, with returns of 31.57% and 39.96% compared to -2.43% and 0.31% for the benchmark, respectively. However, the one-year return is negative at -2.67%, while the S&P 500 has gained 13.36%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

-324.88%

EBIT to Interest (avg)

-177.04

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.76

Sales to Capital Employed (avg)

Tax Ratio

0.05%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.62

EV to EBIT

-7.98

EV to EBITDA

-8.00

EV to Capital Employed

11.77

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-147.42%

ROE (Latest)

-30.50%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 53 Schemes (43.43%)

Foreign Institutions

Held by 92 Foreign Institutions (13.34%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -95.56% vs -78.84% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-72.80",
          "val2": "-44.10",
          "chgp": "-65.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-66.10",
          "val2": "-33.80",
          "chgp": "-95.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -116.79% vs -111.06% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-216.70",
          "val2": "-93.00",
          "chgp": "-133.01%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-182.10",
          "val2": "-84.00",
          "chgp": "-116.79%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-72.80

-44.10

-65.08%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-66.10

-33.80

-95.56%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -95.56% vs -78.84% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-216.70

-93.00

-133.01%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-182.10

-84.00

-116.79%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -116.79% vs -111.06% in Dec 2023

All Annual Results

Company CV

About Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Apogee Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Apogee Therapeutics, Inc.?

Watch in Real-Time

What does Apogee Therapeutics, Inc. do?

Is Apogee Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Apogee Therapeutics, Inc. technically bullish or bearish?

Is Apogee Therapeutics, Inc. technically bullish or bearish?

Is Apogee Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Apogee Therapeutics, Inc.

Company Coordinates